WTR Healthcare Happenings

PharmAla Biotech pivots to proprietary IP, securing GMP manufacturing for ALA-002 and advancing APA-01 neuroplastigen program

22 min Listen to the original
PharmaceuticalsBiotechClinical TrialsMergers & AcquisitionsRegulatoryIntellectual PropertyNeuroscienceMarket Expansion

Summary

CEO Tim Gerdeman introduces CEO Nick Kadysh and Analyst Robert Sassoon to discuss PharmAla Biotech's strategic shift from generic MDMA supply to proprietary intellectual property. Kadysh highlights a manufacturing agreement with Coriolis Pharma to produce GMP drug product for ALA-002, aiming to trigger Jupiter Neurosciences' development timeline before year-end. The company also secured a data license from Aalborg University Hospital regarding MDMA adjunct therapies and replaced its New Zealand distributor with Rua Bioscience. Kadysh emphasizes the high value of the APA-01 neuroplastigen candidate, citing industry precedent, and notes plans for GLP toxicology completion and potential First-in-Human trials in 2028.

Episode sections

  1. 0:00 – 2:02

    Introduction and Company Strategy Shift

    Tim Gerdeman introduces guests Nick Kadysh (CEO/President) and Robert Sassoon (Analyst) for PharmAla Biotech (MDMA). Kadysh states the company's strategy remains unchanged but focus has shifted from generic MDMA supply to proprietary intellectual property, specifically manufacturing GMP drug product for ALA-002.

  2. 2:02 – 4:18

    ALA-002 Manufacturing and Coriolis Pharma Agreement

    Kadysh discusses the agreement with Coriolis Pharma to manufacture GMP drug product for ALA-002. He aims to complete the GMP run before the end of the year to trigger Jupiter Neurosciences' development timeline, noting that failure to do so could revert the license to PharmAla.

  3. 4:18 – 6:31

    Jupiter Neurosciences Licensing and Revenue Model

    The host references the Jupiter Neurosciences agreement: $3.3M upfront, up to $97M in milestones, and 3% royalty. Kadysh confirms that while Jupiter could manufacture its own supply, they likely won't, making PharmAla's manufacturing a key revenue stream and development accelerator.

  4. 6:31 – 12:01

    Aalborg University Hospital Agreement and Clinical Data Value

    Kadysh details the agreement with Aalborg University Hospital for supplying Linneo (generic MDMA) in exchange for a perpetual license to anonymized clinical data. He emphasizes the strategic value of this data for understanding adjunct therapies (music vs. psychotherapy) to address insurance and regulatory questions.

  5. 12:01 – 15:13

    New Zealand Distribution and Rua Bioscience Partnership

    Following MedSafe's authorization for psychiatrists to prescribe MDMA for PTSD in New Zealand, PharmAla partnered with Rua Bioscience. Kadysh replaced previous partner Viridian due to lack of progress, citing Rua's strong regulatory relationships and interest. He views NZ as a small, non-material market in the near term.

  6. 15:13 – 16:42

    Global Market Opportunities and APA-01 Strategy

    Kadysh identifies new patient treatments and expanding to new markets as the largest near-term opportunities, anticipating a 'sea change' if Resilient Therapeutics secures FDA approval. He highlights APA-01, a neuroplastigen candidate, as potentially worth more than the rest of the portfolio combined if advanced successfully.

  7. 16:42 – 18:20

    Financial Outlook and Conclusion

    Kadysh announces that audited financials for the year ended August will be published this month, expecting meaningful progress. He reiterates that long-term revenue will come from IP and proprietary drugs like APA-01, while ALA-002 drives medium-term revenue by replacing generic MDMA.

  8. 18:20 – 22:24

    APA-01 Development and GLP Timeline

    After canceling the licensing of APA-01 to Restora, PharmAla retained full ownership. Kadysh notes strong interest in neuroplastigens (citing D-Lex's $100M raise with J&J). He aims to finish GLP toxicology by next year and initiate First-in-Human trials in early 2028 for post-stroke rehabilitation.

Claims worth verifying

PharmAla Biotech trades on the Canadian Stock Exchange under ticker MDMA and OTCQB under ticker MDXXF.

Tim Gerdeman ·0:09

How to verify: Check CSE and OTCQB filings or market data providers for ticker symbols. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla received $3.3 million upfront from Jupiter Neurosciences, with up to $97 million in potential milestones and a 3% royalty on US net sales.

Unidentified speaker (UNKNOWN) ·4:27

How to verify: Review PharmAla Biotech press releases or SEC/SEDAR filings regarding the Jupiter Neurosciences licensing agreement. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla aims to complete the GMP run for ALA-002 before the end of the year (2026).

Unidentified speaker (speaker_3) ·3:39

How to verify: Monitor PharmAla Biotech press releases for announcements regarding the completion of the GMP batch. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

The Aalborg University Hospital agreement includes a material cash payment and a perpetual worldwide license to anonymized clinical data.

Unidentified speaker (speaker_3) ·7:54

How to verify: Review PharmAla Biotech press releases or filings detailing the Aalborg University Hospital supply and data license agreement. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

New Zealand's MedSafe authorized psychiatrists to prescribe MDMA for PTSD.

Unidentified speaker (speaker_2) ·12:01

How to verify: Check MedSafe (New Zealand Medicines and Medical Devices Safety) announcements or regulatory databases for MDMA prescribing authorizations. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

D-Lex raised $100 million with Johnson & Johnson as the lead investor for a neuroplastigen drug candidate.

Unidentified speaker (speaker_3) ·20:16

How to verify: Search for D-Lex Therapeutics press releases or news reports regarding the $100M funding round and Johnson & Johnson investment. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla canceled the proposed licensing of APA-01 to Restora in August.

Unidentified speaker (speaker_3) ·18:27

How to verify: Review PharmAla Biotech press releases or filings from August 2026 regarding the Restora transaction and APA-01 ownership. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla plans to finish GLP toxicology for APA-01 by next year (2027) and initiate First-in-Human trials in early 2028.

Unidentified speaker (speaker_3) ·21:21

How to verify: Monitor PharmAla Biotech press releases for updates on APA-01 clinical trial initiation timelines. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla's audited financials for the year ended August will be published in the current month (November 2026).

Unidentified speaker (speaker_3) ·17:11

How to verify: Check PharmAla Biotech investor relations website or SEDAR filings for the publication of audited financial statements. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

PharmAla replaced its New Zealand distributor from Viridian to Rua Bioscience.

Unidentified speaker (speaker_3) ·13:18

How to verify: Review PharmAla Biotech press releases or filings announcing the change in distribution partners for New Zealand. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Verify the status of the Coriolis Pharma manufacturing agreement and the specific contractual triggers for the ALA-002 GMP run completion.
  • Review the full Jupiter Neurosciences licensing agreement details, including the $3.3M upfront payment, $97M milestones, and 3% royalty terms.
  • Analyze the anonymized clinical data from Aalborg University Hospital to assess the efficacy of MDMA with music therapy versus psychotherapy.
  • Check the current regulatory status of MDMA for PTSD in New Zealand and the operational progress of the new distributor, Rua Bioscience.
  • Evaluate the competitive landscape for APA-01 and other neuroplastigen candidates, referencing the D-Lex/J&J transaction for valuation benchmarks.
  • Confirm the timeline for APA-01 GLP toxicology studies and the projected start of First-in-Human trials in early 2028.
  • Review PharmAla's audited financials for the year ended August to assess cash runway and progress against stated milestones.
  • Investigate the specific engagement with Veterans Affairs Canada regarding protocol validation and potential commercial opportunities.
Full transcriptexpand

0:00Tim Gerdeman: Welcome to the WTR Healthcare Happenings Podcast. I'm your host, Tim Gerdeman, co-founder of Water Tower Research.

0:08Unidentified speaker (UNKNOWN): In

0:09Tim Gerdeman: today's podcast episode, I'm being joined by Nick Cadish, founding CEO and president of Farmalla Biotech, Canadian Stock Exchange ticker MDMA, and OTC QB ticker symbol MDXXF. Also joining is my WTR uh colleague Robert. Sassoon, WTR's healthcare analyst. Welcome back to the podcast, Nick and Robert.

0:33Unidentified speaker (speaker_1): Good to be here. Thanks very much.

0:35Unidentified speaker (speaker_2): Thanks, Tim. And good to see you again, Nick. Let's start with a bigger picture. Farmala has been active on several fronts recently with the agreements covering proprietary drug development, clinical grade MDMA supply, and international distribution. How would you describe the company's evolution at this stage? And how do you see the manufacturing and supply business complementing the longer-term opportunity in developing and licensing proprietary MDXX compounds?

1:02Unidentified speaker (speaker_3): Um, yeah, thanks very much. So uh nobody wants to hear me say this, but actually, like our strategy hasn't changed Change at all. Everything continues exactly as it was. Um, I think it if anything, there is one sort of change. in focus, which is uh we're less interested in just supplying MDMA uh at this point. Um I think the future of the company very clearly lies in proprietary intellectual property. Um, and that's why we've been working so hard to manufacture the drug product for ALA 02. Um, the recent announcement we made that um that we were going to supply University of Auburg is sort of an interesting case. Uh, and I'm happy to get into it more. But um, you know, in terms of our focus and our desire, sure we want to supply MDMA to patients, um, but but clinical trials, unless they have something unique to offer, it's it's just gonna be less of a focus for us moving forward.

2:02Unidentified speaker (speaker_2): Right. Great. So let's delve into those uh deals that you've recently announced. And you let's start with uh you recently signed a uh agreement with the Coriolis uh pharma which is a Canadian CEO

2:14Unidentified speaker (UNKNOWN): uh

2:15Unidentified speaker (speaker_2): to develop and manufacture the finished GMP drug product for ALA 002 initially as our 50 milligram capsule so you had previously completed GMP manufacturing of the drug substance how important is this next step in moving ALA 002 toward clinical testing? What remains to be completed before the first GMP batch is released? And what is your current timeline for getting the product ready for clinical use?

2:40Unidentified speaker (speaker_3): Uh so uh how important is it? Like it's very important, obviously. You know, you can't just like sprinkle some powder on people's tongues. Uh, you know, you do need a finished dose, uh, especially when with this. Uh, it is a controlled substance. Um, we went through, I wouldn't say hell, but our but our product team really went through a very difficult time getting the product QP released for our customers in um in uh Europe. And this is for, of course, the generic product. So for ALA 02, we didn't want to waste uh time reinventing the wheel. We wanted to make sure that everything was done at a high level. We're very happy to be onshoring manufacturing in Canada right now. There's a number of reasons for that, but the business environment in Canada has definitely improved. And uh and we're we're quite pleased thus far with Coriolis and what they bring to the table. Um my hope, and it is just a hope at this point. because it's still future-facing, and I don't know whether we're gonna make it, but my hope would be that we get the GMP run done before the end of this year. Uh, I don't know if we're gonna get the product released before the end of this year, but my hope is to get it done. And we do have like quite a bit of interest in um in the ALA drug product. So once it's

3:59done, it's not, you know, it's not just our own clinical trials, right? There are there are many, many, many uh sort of folks out there, including in the academic world, who are hungry for novel, uh sort of a novel composition to test. So we'd we'd definitely like to get it done and out the doors so we can uh you know get get this tested.

4:18Unidentified speaker (speaker_2): Yeah, understood. So under the Jupiter Neurosciences Licensing Agreement, Falmala Farmala received 3.3 million dollars upfront. up front, that's US dollars,

4:27Unidentified speaker (UNKNOWN): with

4:28Unidentified speaker (speaker_2): up to an 97 million around $97 million in uh potential milestones and a 3% royalty on US net sales. So you have indicated that Jupiter Jupiter can either purchase GMP supply from Farmala or manufacture its own supply in the US. How do you see the manufacturing relationship evolving? And how important could drug product uh manufacturing become as an additional revenue stream? alongside licensing milestones and royalties?

4:54Unidentified speaker (speaker_3): So uh look, I think it is if it is very important. It's important in two ways. Um, the one is that you mentioned, uh, could Jupiter manufacture their own? Sure. Will they? No. That'd be crazy. Why would you reinvent the wheel? We already have the drug product, it's made. Right. Um, but uh there's another element to this. Uh so yes, like there is additional revenue that could. come from that and it sort of would drive Jupiter's development, accelerate their development, but also help us, you know, by by bringing in additional revenue. There's another element to this, which is we tied the initiation of development diligence for Jupiter to the completion of the drug product. So we are racing to get that drug product done because the moment that we get it done, that starts Jupiter's timeline to do their pre IND work, to get their IND into the FDA and to basically move this along. And of course, if they don't, the license reverts back to us. So as with all of our partners, uh, we I say this at the beginning we will do our part, then you got to do yours.

5:54Unidentified speaker (speaker_2): Right.

5:55Unidentified speaker (UNKNOWN): So

5:55Unidentified speaker (speaker_2): uh with Coriolis having uh a separate manufacturing relationship with rot Rotendorf Pharma Farmer in Germany for late for a later stage in commercial. production. Could that actually provide a perth pathway to scale LAA 002 manufacturing as the program advances?

6:12Unidentified speaker (UNKNOWN): Uh

6:12Unidentified speaker (speaker_3): look potentially we have not discussed it uh like at all. Uh we're we're really laser focused on just getting this badge done and we have really big plans for it. Um you know we've we've already advanced like several commercial discussions. We just gotta get got this thing to done before the end of the year. That's a real priority.

6:29Unidentified speaker (speaker_2): Right. So let's go back to the uh let's go to the second uh um agreement that you've reached with Alberg uh University Hospital in Denmark. Something you uh uh mentioned earlier on. And that's particularly interesting because in addition to cash payment for supplying Laneo farm, Farmala receives a perpetual worldwide license. to the study's anonymized clinical data, including safety, dosing and effect efficacy analyses, with a right to sub license the data to partners. How strategically valuable is this arrangement? And could this clinical data eventually become a meaningful asset in its own right, supporting regulatory submissions, commercial partnerships, and the development of your own MDXX MDAXX programs?

7:13Unidentified speaker (UNKNOWN): Yeah,

7:14Unidentified speaker (speaker_3): like look this is exactly what I mean. Uh I, you know, if we had our ALA program done before the end of last year rather than before the end of this year, there's probably a meaningful chance that we could have gotten Alberg to to use ALA instead of using Linneo, the genericum DMA product, right? So it's why it's so important that we get it done. Um I I think several things about that. Number one. um, you know, there's a commercial component to that transaction, like a cash component. Uh, I don't think we've announced how much it is, but it is it is like material. Um, I like in an accounting sense. So it's a significant cash payment. Um and then yeah, the the data. So I mentioned earlier, like we want to get away from Lineo, uh supplying Lineo to clinical trials, unless there's something special about those trials. And in this context, I think there actually is. So, number one, Renee, who's the PI for this trial, is like a world-class researcher, the the kind of person that we want to work with. And two, the thing that he's studying is actually the very, very topical matter, which is uh they're testing MDMA with different forms of therapy. So they're doing music therapy and then psychotherapy. I believe CPT, but don't quote me on that. And that's very, very valuable data because one of the questions that we get asked in places like Australia, in places like Canada, where there is actual access to the drug,

8:34uh, comes from insurance companies. And they say, okay, fine, like we believe that MDMA is effective at treating PTSD. But what we don't have an answer for is what is the adjunct therapy supposed to look like? And there's not a lot of data on what is more effective or less effective. Uh maybe. what the conclusion will be of this trial is that like, you know, they're all equally effective and it's just a drug at work, and yay, that'd be great. But um for commercial purposes, I would be very, very interested to see what the what the answer is. And that's why we fought so hard to get access to this data. It's very valuable data.

9:08Unidentified speaker (UNKNOWN): Yeah,

9:08Unidentified speaker (speaker_2): so you you brought that up, and uh the follow-up question is what uh you know, the mirror study, which uh Alberg is uh university is is conducting, and you mentioned comparing you know treatment for service-related PTSD using conventional psychotherapy and against uh music assisted relaxation, which is a far less uh intensive uh therapeutic approach.

9:32Unidentified speaker (UNKNOWN): Uh

9:33Unidentified speaker (speaker_2): so that addresses the important question about how much of the treatment depends on the accompanying psychotherapy. So, what could the result? results tell us about the scalability and economics of MDMA assisted treatment and how might the findings influence Farmala's commercial strategy?

9:47Unidentified speaker (speaker_3): So, uh look, again, I think if if we find out that both therapy modalities, like music therapy, which as you say is like very low pressure, uh is equally uh potent uh uh as compared to traditional psychotherapy, that certainly means that we can deliver MDMA assisted therapy much more cheaply, right? Like uh do it in a group setting, you know, play some music, relax, it's all good. Um that does have one drawback, though, I will say, which is um, you know, this the psychotherapy component is a is a big part of what drives clinics to onboard MDMA as a treat. treatment, because they can charge for those hours for those therapies. Once they're onboarded, they all want to drive down costs. But at the beginning, you know, like having the ability to sort of to bill for that is really important. So I don't yet know how it'll affect our um our um sort of commercial plans, but I will say that knowing this and having access to that data, exclusive access.

10:51to that data before everybody else, it's going to be very valuable for us.

10:55Unidentified speaker (speaker_2): Right.

10:56Unidentified speaker (UNKNOWN): I

10:56Unidentified speaker (speaker_2): remember Richard Doblin used to say that, you know, that was with psychotherapy, the therapeutic uh the psychopathy part of the uh the treatment was probably critically the most critical, uh and that MDMA was really

11:09Unidentified speaker (UNKNOWN): good

11:10Unidentified speaker (speaker_2): data. So yeah.

11:11Unidentified speaker (UNKNOWN): Yeah, look, I I

11:12Unidentified speaker (speaker_3): I look I I agree, but at the same time, like all of the maps trials, they used like a non-standard form of psychotherapy as well. And I

11:19Unidentified speaker (UNKNOWN): can

11:19Unidentified speaker (speaker_3): tell you, like, we recently had a call with the Canadian um uh Veterans Affairs Canada, which is our sort of veterans bureaucracy. And and this was their big this is their big problem. Dude, they said, Look, you we we don't know what kind of therapy to use. None of this stuff is validated. Like the drug, sure, but what about everything else? Uh and so being able to answer that question for them in a in a legitimate way, it's it's kind of critical.

11:42Unidentified speaker (speaker_2): Yeah. All right. Well, uh we're definitely gonna monitor what's going on with that. Uh anyway, uh moving on, uh, you know, your October your October agreement with the Ruhr Bioscience gives uh Farmala's distribution partner, uh, a distribution partner for Laneo in New Zealand, following MedSafe's uh decision to allow author authorized authorised psychiatrists to prescribe MDMA. for PTSD, pretty much in the same way that uh, you know, Australia started in uh the middle of uh two thousand twenty three, I believe. Uh Ruha will initially receive a product on a consignment basis, limiting its upfront capital commitment. How large an opportunity do you see in New Zealand? What needs to happen before the first commercial shipments and patient treatments begin? And what kind of revenue contribution could this market ev eventually make?

12:28Unidentified speaker (speaker_3): So look, New Zealand is a small market. I think everyone acknowledges this. It is not going to be like material for a couple of years at least. But it happens to be very close to Australia and has very close ties to Australia. And we happen to have a lot of MDMA sitting in Australia that we use either for Cortexa, we did our last Linneo Lineo MDMA manufacturing run in Australia. So um that that gives us a great great opportunity to sort of go into that market full bore and quickly. Um the Rua folks really impressed us. So uh we we had a different distribution partner called Viridian. And you know, right before the news sort of hit that um MedSafe was going to When allow MDMA assistant system therapy, you know, we signed Viridian over a year ago, and there really wasn't any like progress. And they were kind of uninterested. It's a weird situation when somebody like comes to you and says, I really want to do this, and you sign a contract and they kind of go, eh. But so uh so we sat there and we waited and we waited and we waited. And eventually I called them and I said, Guys, like if you're not interested, then at least like real like we don't owe anybody anything. You don't owe us anything, I don't owe you anything. Let release this to somebody who actually gives a damn. And they said, you know, they're good guys. I have no, I have no complaints. They were like, yeah, okay. Fair

13:45enough. So we found the folks at Rua. And they are number one, they're very, very interested in the space. They already do some psilocybin work. More importantly, uh, you know, we value very highly in our partners um uh a high sort of uh regulatory capability, good relationship. with regulators, trustworthy, plays by the rules, right? When you work in controlled substances, kind of important. And the Rua guys really blew our socks off. Like they're very close to MedSafe. They know what they're doing, they really try hard and they're successful, generally speaking. And so um, yeah, we're looking forward to it. Again, don't expect it to be a big market, not quickly. Um, it I really frankly, I don't expect it to be a huge market ever. It's New Zealand. Uh, but uh additional data. And in terms of US next steps, uh, the first step, which has already happened, is a number of doctors must apply to MedSafe uh to get their authorized prescriber status. Happy to say that's already happened. Um, we actually, you know, we were corresponding with MedSafe last week about this. Uh so now it's just a question of as soon as they get their approvals, we start importing the drug to Rua and they start distributing it.

14:56Unidentified speaker (speaker_2): Okay.

14:56Unidentified speaker (UNKNOWN): So

14:57Unidentified speaker (speaker_2): across Australia, New Zealand, Europe, and a possible US access pathway under the ex Trump's executive order earlier this year. Where do you see the largest near-term opportunity? Is it clinical trial supply, authorized patient treatment, or new distribution partners?

15:13Unidentified speaker (speaker_3): Um look, uh new patient treatments and uh expanding to new markets. Of course, we would like to see uh Resilient get their approval. Uh they deserve it, frankly. And there are a whole host of markets that are ready to go. Um, you know, as soon as as soon as that approval comes through, I think it's a sea change. And we happen to be in a position where we sort of have a dossier ready to file in a number of markets. Uh Um, I think before FDA renders their verdict, probably a hard sell host approval, much, much easier. So we are in discussions with a number of distributors, but it's not just a question of just getting distribution partners. It's a question of getting distribution partners, again, who have that regulatory capacity to make a filing, move this process along from a regulatory uh standpoint. And then of course, you know, having ALA 02 drug product ready to go means clinical trial supply with ALA. Um, you know, testing uh the benefits of ALA in market

16:13where we can. Uh there will be there will be some announcements on that uh in the near in the near

16:19Unidentified speaker (UNKNOWN): term. Good.

16:22Unidentified speaker (speaker_2): We'll look forward to that. So looking ahead over the next 12 to 18 months, there are several important milestones. Completion of the first GMP GMP LAA 002 drug product batch, which we were talking about earlier, initiation of clinical development for ALA 002 in Australia for social anxiety disorder, potential additional licensing partnerships, and growth in the NEO supply agreements and international distribution. Which of these milestones do you believe will be the most important in demonstrating that Falmara strategy is actually translating into commercial progress? And what should investors look for in terms of revenue growth and cash generation ahead?

16:59Unidentified speaker (UNKNOWN): Yeah,

17:00Unidentified speaker (speaker_3): well, look, uh we will be publishing our audited financials. You know, if if my guys do do their jobs, we'll be publishing our audited financials for the year ended in August this month. Uh I think it'll show some very very meaningful progress on our financials. And, you know, hopefully, uh based on what we've announced, I think people can expect to see like great strides being made. Um so uh I think in the long term, the majority of our revenue will come from IP, actually. We've already proven that we can commercialize our IP and we can commercialize it well. Uh that will take a number of forms, though. That will, you know, also take the form of I'd like to sell some of these patented drugs directly to patients, not just sell the generic MDMA. So uh our our focus, you know, uh I'm I'm spending a lot of time in Europe talking about APA zero one. There's a lot of interest in neuroplastigens right now. I think we still have a ways to go in developing that drug, but I think it's going to be worth more than the rest of our. portfolio combined, what it's done, uh, as long as we

18:05can advance it through the clinical trial pathway. Um and then and then yeah, getting getting folks moved over from generic MDMA to ALA, that will drive the most revenue um in the medium term.

18:19Unidentified speaker (speaker_2): Right.

18:19Unidentified speaker (UNKNOWN): So

18:20Unidentified speaker (speaker_2): you mentioned uh you're in the uh you've been in Europe uh, you know, uh presenting uh uh APA zero one. So

18:27Unidentified speaker (speaker_3): yeah

18:27Unidentified speaker (speaker_2): following Farma's decision to in August to cancel the proposed licensing of APA zero one to Restora, although it seems like you've kept it in Restora and kept uh

18:37Unidentified speaker (UNKNOWN): just

18:37Unidentified speaker (speaker_2): running a hundred percent now and uh retaining full ownership on the compound and its intellectual property for the you know you're you subsequently presented a you APA zero one data in Europe bio uh bio Europe. in Cologne and you participated in London Life Sciences week uh week. What was a rationale of presenting the data at this stage? Were you primarily looking primarily looking to identify new development partners, potential licensees or investors to help advance the program? And has the interest have you seen any interest that's been generated through these presentations that have influenced your thinking about how best to develop and commercialise commercialize AP? APA 01.

19:17Unidentified speaker (speaker_3): Yeah, absolutely. Uh so the first thing I will say is yes, you're absolutely right. So we've kept the the the we've the restorative branding, the entity that we built up or filed, whatever. I don't know what you call it when you make a new corporation, but we we've kept that 100% wholly Percent owned by Farbala. We are very confident that that was the right decision because I think everyone has sort of said the same thing, which is uh, yes, this is not MDMA. This is a different thing. And uh I think I've learned that uh there's two kinds of investors in the world. Uh, there are the people who want to invest in an MDMA company and the people who do not. Um, and so keeping this asset, which is very much not MDMA, uh, out from the from from sort of the rest of the MDMA business, I think that is the right sort. strategy. What we're hearing about this drug is number one, like this is a neuroplastigen, and there is a ton of interest in neuroplastigens right now. So D-Lex, which has a neuroplastigen drug candidate going into phase two, I believe, just raised $100 million with Johnson and Johnson being the lead investor.

20:22These are these are very, very valuable programs if you can bring them along. And so we have begun presenting data. We have a lot of data. It is non GLP data, meaning that we still have to like repeat sort of the toxicology that we've done in order to get it into an I and D. We can do it relatively quickly because we know where the where the red lines are. It's a very safe drug, uh, and it has applicability in a number of disorders. Uh we are looking at uh post post-stroke stroke neural rehabilitation, but there's also applicability in other stuff. Apathy, which is one of the things that happens when you have a stroke. You get apathy, you remove yourself from life. That's also a feature of Parkinson's, for instance. So we we have just we found a lot of interest from a lot of different parties, grant funding organizations, uh potential outlicensing out licensing organizations, like Big Pharma and um uh and and and other partners like IIT. partners. So uh we are spending a lot of time trying to advance this drug. Um and you know if I have my druthers by this time next year we will be finishing up the GLP talks and getting it into first in human you know early 2028 if we can. Fingers crossed.

21:32Unidentified speaker (speaker_2): Great. So I'll wrap it up there. Great a lot of interesting things to to look forward to with the uh LA ALA zero 002 and APA zero one, it seems. So thanks, Nick, for guiding us through the latest meaningful developments of Farmola, and I'll pass it back to Tim.

21:47Tim Gerdeman: Thanks, Robert, and thanks, Nick, for joining us to talk about the exciting developments. We hope to have you back on as uh the story continues to evolve. Thank you for listening, and don't forget to subscribe, as well as visiting WW wwwwatertower Watertower Research.com to stay up to speed on the company's small cap written research reports, podcasts, fireside chats, industry-specific symposiums, and conference schedules. We will see you next time for another edition of the WTR Small Cap Spotlight Podcast. Finally, a special thanks to the producer and editor of the podcast, Krista Fitzpatrick.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights